Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Glaxo Takes $2.36 bln Charge on Legal Costs

By Pharmaceutical Processing | July 15, 2010

LONDON (AP) — GlaxoSmithKline said today it expects to take a $2.36 billion charge against second-quarter earnings for the costs of settling court cases over the antidepressant Paxil and diabetes drug Avandia.

The company said the charge includes settlements, agreements to settle and other provisions for long-standing legal cases which also include an investigation of its facility in Cidra, Puerto Rico.

The announcement comes a day after a U.S. Food and Drug Administration panel of experts voted to allow Avandia to remain on the market. The drug faces another review by the European Medicines Agency.

GlaxoSmithKline shares were up 1.6 percent at 1,200 pence in morning trading on the London Stock Exchange.

Glaxo said it has settled the vast majority of product liability cases involving Paxil, which has been linked to birth defects, and a substantial majority of liability cases involving Avandia, which has been associated with a higher risk of heart disease. GSK said it has settled antitrust litigation involving Canadian drug maker Apotex Inc.

The charge also includes an agreement to pay $750 million to settle an investigation of problems at the company’s plant in Puerto Rico.

“The charge we have announced today reflects the company’s ongoing efforts to resolve certain long-standing legal cases,” said Dan Troy, GSK’s general counsel.

“This represents a substantial proportion of GSK’s outstanding litigation. This progress is helping us to reduce financial uncertainty and risk for shareholders.”

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE